Acetylcholinesterase (AChE) inhibitors are widely used for the symptomatic treatment of Alzheimer's disease and other dementias. More recent use is for myasthenia gravis. Many of these inhibitors interact with the second known cholinesterase, butyrylcholinesterase (BChE). Further, evidence shows that acetylcholine plays a role in suppression of cytokine release through a "cholinergic anti-inflammatory pathway" which raises questions about the role of these inhibitors in the immune system. This review covers research and discussion of the role of the inhibitors in modulating the immune response using as examples the commonly available drugs, donepezil, galantamine, huperzine, neostigmine and pyridostigmine. Major attention is given to the cholinergic anti-inflammatory pathway, a well-described link between the central nervous system and terminal effector cells in the immune system.

Faculty of Military Health Sciences University of Defence Trebesska 1575 Hradec Kralove CZ 50001 Czech Republic

Zobrazit více v PubMed

Ofek K., Soreq H. Cholinergic involvement and manipulation approaches in multiple system disorders. Chem. Biol. Interact. 2013;203:113–119. doi: 10.1016/j.cbi.2012.07.007. PubMed DOI

De los Rios C. Cholinesterase inhibitors: A patent review (2007–2011) Expert Opin. Ther. Pat. 2012;22:853–869. doi: 10.1517/13543776.2012.701619. PubMed DOI

Silman I., Sussman J.L. Acetylcholinesterase: “Classical” and “non-classical” functions and pharmacology. Curr. Opin. Pharmacol. 2005;5:293–302. doi: 10.1016/j.coph.2005.01.014. PubMed DOI

Tayeb H.O., Yang H.D., Price B.H., Tarazi F.I. Pharmacotherapies for Alzheimer’s disease: Beyond cholinesterase inhibitors. Pharmacol. Ther. 2012;134:8–25. PubMed

Haines S.R., Thurtell M.J. Treatment of ocular myasthenia gravis. Curr. Treat. Option Neurol. 2012;14:103–112. PubMed

Marrs T.C., Maynard R.L. Neurotranmission systems as targets for toxicants: A review. Cell Biol. Toxicol. 2013;29:381–396. doi: 10.1007/s10565-013-9259-9. PubMed DOI

Colovic M.B., Krstic D.Z., Lazarevic-Pasti T.D., Bondzic A.M., Vasic V.M. Acetylcholinesterase inhibitors: Pharmacology and toxicology. Curr. Neuropharmacol. 2013;11:315–335. doi: 10.2174/1570159X11311030006. PubMed DOI PMC

Rakowski F., Srinivasan J., Sternberg P.W., Karbowski J. Synaptic polarity of the interneuron circuit controlling c. Elegans locomotion. Front. Comput. Neurosci. 2013;7:128. PubMed PMC

Kosinski R.A., Zaremba M. Dynamics of the model of the caenorhabditis elegans neural network. Acta Phys. Pol. B. 2007;38:2201–2210.

Rand J.B. Acetylcholine. WormBook. 2007 doi: 10.1895/wormbook1.131.1. PubMed DOI PMC

Pohanka M. Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology. Int. J. Mol. Sci. 2012;13:2219–2238. PubMed PMC

Bellier J.P., Kimura H. Peripheral type of choline acetyltransferase: Biological and evolutionary implications for novel mechanisms in cholinergic system. J. Chem. Neuroanat. 2011;42:225–235. doi: 10.1016/j.jchemneu.2011.02.005. PubMed DOI

Wessler I., Kirkpatrick C.J. Acetylcholine beyond neurons: The non-neuronal cholinergic system in humans. Br. J. Pharmacol. 2008;154:1558–1571. doi: 10.1038/bjp.2008.185. PubMed DOI PMC

Rosas-Ballina M., Tracey K.J. Cholinergic control of inflammation. J. Intern. Med. 2009;265:663–679. PubMed PMC

Bernik T.R., Friedman S.G., Ochani M., DiRaimo R., Ulloa L., Yang H., Sudan S., Czura C.J., Ivanova S.M., Tracey K.J. Pharmacological stimulation of the cholinergic antiinflammatory pathway. J. Exp. Med. 2002;195:781–788. doi: 10.1084/jem.20011714. PubMed DOI PMC

Borovikova L.V., Ivanova S., Zhang M.H., Yang H., Botchkina G.I., Watkins L.R., Wang H.C., Abumrad N., Eaton J.W., Tracey K.J. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000;405:458–462. doi: 10.1038/35013070. PubMed DOI

Ofek K., Krabbe K.S., Evron T., Debecco M., Nielsen A.R., Brunnsgaad H., Yirmiya R., Soreq H., Pedersen B.K. Cholinergic status modulations in human volunteers under acute inflammation. J. Mol. Med. 2007;85:1239–1251. PubMed

Andersson U., Tracey K.J. Neural reflexes in inflammation and immunity. J. Exp. Med. 2012;209:1057–1068. doi: 10.1084/jem.20120571. PubMed DOI PMC

Pavlov V.A., Ochani M., Gallowitsch-Puerta M., Ochani K., Huston J.M., Czura C.J., Al-Abed Y., Tracey K.J. Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia. Proc. Natl. Acad. Sci. USA. 2006;103:5219–5223. doi: 10.1073/pnas.0600506103. PubMed DOI PMC

Pavlov V.A., Parrish W.R., Rosas-Ballina M., Ochani M., Puerta M., Qchani K., Chavan S., Al-Abed Y., Tracey K.J. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain Behav. Immun. 2009;23:41–45. doi: 10.1016/j.bbi.2008.06.011. PubMed DOI PMC

Tracey K.J. The inflammatory reflex. Nature. 2002;420:853–859. doi: 10.1038/nature01321. PubMed DOI

Tracey K.J. Reflex control of immunity. Nat. Rev. Immunol. 2009;9:418–428. doi: 10.1038/nri2566. PubMed DOI PMC

Wang H., Yu M., Ochani M., Amella C.A., Tanovic M., Susarla S., Li J.H., Wang H.C., Yang H., Ulloa L., et al. Nicotinic acetylcholine receptor alpha 7 subunit is an essential regulator of inflammation. Nature. 2003;421:384–388. doi: 10.1038/nature01339. PubMed DOI

Wang H., Liao H., Ochani M., Justiniani M., Lin X.C., Yang L.H., Al-Abed Y., Wang H.C., Metz C., Miller E.J., et al. Cholinergic agonists inhibit hmgb1 release and improve survival in experimental sepsis. Nat. Med. 2004;10:1216–1221. doi: 10.1038/nm1124. PubMed DOI

Silva-Herdade A.S., Saldanha C. Effects of acetylcholine on an animal mode of inflammation. Clin. Hemorheol. Microcirc. 2013;53:209–216. PubMed

Coin A., Perissinotto E., Catanzaro S., Mosele M., de Rui M., Girardi A., Inelmen E.M., Toffanello E.D., Manzato E., Sergi G. Effects of 21 months of cholinesterase inhibitors on cognitive and functional decline in demented patients. Aging Clin. Exp. Res. 2012;24:14–16. PubMed

Iwasaki T., Yoneda M., Nakajima A., Terauchi Y. Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance. Intern. Med. 2007;46:1633–1639. doi: 10.2169/internalmedicine.46.0049. PubMed DOI

Karlsson D., Fallarero A., Brunhofer G., Mayer C., Prakash O., Mohan C.G., Vuorela P., Erker T. The exploration of thienothiazines as selective butyrylcholinesterase inhibitors. Eur. J. Pharm. Sci. 2012;47:190–205. doi: 10.1016/j.ejps.2012.05.014. PubMed DOI

Pohanka M. Cholinesterases, a target of pharmacology and toxicology. Biomed. Pap. 2011;155:219–229. doi: 10.5507/bp.2011.036. PubMed DOI

Noelker C., Stuckenholz V., Reese J.P., Alvarez-Fischer D., Sankowski R., Rausch T., Oertel W.H., Hartmann A., van Patten S., Al-Abed Y., et al. Cni-1493 attenuates neuroinflammation and dopaminergic neurodegeneration in the acute mptp mouse model of Parkinson’s disease. Neurodegener. Dis. 2013;12:103–110. doi: 10.1159/000342714. PubMed DOI

Lee L., Kosuri P., Arancio O. Picomolar amyloid-beta peptides enhance spontaneous astrocyte calcium transients. J. Alzheimers Dis. 2014;38:49–62. PubMed PMC

Sun P., Zhou K.W., Wang S., Li P., Chen S.J., Lin G.P., Zhao Y., Wang T.H. Involvement of mapk/NF-κB signaling in the activation of the cholinergic anti-inflammatory pathway in experimental colitis by chronic vagus nerve stimulation. PLoS One. 2013;8:e69424. PubMed PMC

De Haan J.J., Hadfoune M., Lubbers T., Hodin C., Lenaerts K., Ito A., Verbaeys I., Skynner M.J., Cailotto C., van der Vliet J., et al. Lipid-rich enteral nutrition regulates mucosal mast cell activation via the vagal anti-inflammatory reflex. Am. J. Physiol.-Gastroint. Liver Physiol. 2013;305:G383–G391. doi: 10.1152/ajpgi.00333.2012. PubMed DOI

Starec M., Sinet M., Kodym P., Rosina J., Fiserova A., Desforges B., Rouveix B. The effect of drugs on the mortality of mice inoculated with friend leukaemia virus or toxoplasma gondii. Physiol. Res. 1997;46:107–111. PubMed

Pohanka M. Role of oxidative stress in infectious diseases. A review. Folia Microbiol. 2013;58:503–513. doi: 10.1007/s12223-013-0239-5. PubMed DOI

Smirnov I., Belogurov A., Friboulet A., Masson P., Gabibov A., Renard P.Y. Strategies for the selection of catalytic antibodies against organophosphorus nerve agents. Chem.-Biol. Interact. 2013;203:196–201. doi: 10.1016/j.cbi.2012.10.011. PubMed DOI

Da Silva V.B., de Andrade P., Kawano D.F., Morais P.A.B., de Almeida J.R., Carvalho I., Taft C.A., da Silva C. In silico design and search for acetylcholinesterase inhibitors in Alzheimer’s disease with a suitable pharmacokinetic profile and low toxicity. Future Med. Chem. 2011;3:947–960. doi: 10.4155/fmc.11.67. PubMed DOI

Krall W.J., Sramek J.J., Cutler N.R. Cholinesterase inhibitors: A therapeutic strategy for alzheimer disease. Ann. Pharmacother. 1999;33:441–450. doi: 10.1345/aph.18211. PubMed DOI

Arduini F., Errico I., Amine A., Micheli L., Palleschi G., Moscone D. Enzymatic spectrophotometric method for aflatoxin b detection based on acetylcholinesterase inhibition. Anal. Chem. 2007;79:3409–3415. doi: 10.1021/ac061819j. PubMed DOI

Arduini F., Amine A., Moscone D., Palleschi G. Biosensors based on cholinesterase inhibition for insecticides, nerve agents and aflatoxin b-1 detection (review) Microchim. Acta. 2010;170:193–214. doi: 10.1007/s00604-010-0317-1. DOI

Brazzolotto X., Wandhammer M., Ronco C., Trovaslet M., Jean L., Lockridge O., Renard P.Y., Nachon F. Human butyrylcholinesterase produced in insect cells: Huprine-based affinity purification and crystal structure. FEBS J. 2012;279:2905–2916. doi: 10.1111/j.1742-4658.2012.08672.x. PubMed DOI

Massoulie J. The origin of the molecular diversity and functional floating of cholinesterases. Neurosignals. 2002;11:130–143. doi: 10.1159/000065054. PubMed DOI

Marrs T.C. Organophosphate poisoning. Pharmacol. Ther. 1993;58:51–66. doi: 10.1016/0163-7258(93)90066-M. PubMed DOI

Furtado M.D., Rossetti F., Chanda S., Yourick D. Exposure to nerve agents: From status epilepticus to neuroinflammation, brain damage, neurogenesis and epilepsy. Neurotoxicology. 2012;33:1476–1490. doi: 10.1016/j.neuro.2012.09.001. PubMed DOI

Dorandeu F., Foquin A., Briot R., Delacour C., Denis J., Alonso A., Froment M.T., Renault F., Lallement G., Masson P. An unexpected plasma cholinesterase activity rebound after challenge with a high dose of the nerve agent vx. Toxicology. 2008;248:151–157. doi: 10.1016/j.tox.2008.03.013. PubMed DOI

Raghu P., Madhusudana Reddy T., Reddaiah K., Swamy B.E., Sreedhar M. Acetylcholinesterase based biosensor for monitoring of malathion and acephate in food samples: A voltammetric study. Food Chem. 2014;142:188–196. doi: 10.1016/j.foodchem.2013.07.047. PubMed DOI

Ahmed M., Rocha J.B., Mazzanti C.M., Morsch A.L., Cargnelutti D., Correa M., Loro V., Morsch V.M., Schetinger M.R. Malathion, carbofuran and paraquat inhibit bungarus sindanus (krait) venom acetylcholinesterase and human serum butyrylcholinesterase in vitro. Ecotoxicology. 2007;16:363–369. doi: 10.1007/s10646-007-0137-1. PubMed DOI

Tian Y., Zhou S.F., Gao Y., Zhou Y.J., Shi R., Heiger-Bernays W., Ding Y., Wang P., Han S., Shen X.M. Effects of repeated maternal oral exposure to low levels of trichlorfon on development and cytogenetic toxicity in 3-day mouse embryos. Food Chem. Toxicol. 2011;49:2655–2659. doi: 10.1016/j.fct.2011.07.011. PubMed DOI

Becker R.E., Unni L.K., Greig N.H. Resurrecting clinical pharmacology as a context for alzheimer disease drug development. Curr. Alzheimer Res. 2009;6:79–81. doi: 10.2174/156720509787313916. PubMed DOI PMC

López-Arrieta J.M., Schneider L. Metrifonate for Alzheimer’s disease. Cochrane Database Syst. Rev. 2006:CD003155. PubMed

Yang Y.X., Niu L.Z., Li S.N. Purification and studies on characteristics of cholinesterases from daphnia magna. J. Zhejiang Univ.-Sci. B. 2013;14:325–335. doi: 10.1631/jzus.B1200113. PubMed DOI PMC

Oropesa A.L., Gravato C., Sanchez S., Soler F. Characterization of plasma cholinesterase from the white stork (ciconia ciconia) and its in vitro inhibition by anticholinesterase pesticides. Ecotoxicol. Environ. Saf. 2013;97:131–138. doi: 10.1016/j.ecoenv.2013.07.022. PubMed DOI

Zawadzka A., Lózinska I., Moleda Z., Panasiewicz M., Czarnocki Z. Highly selective inhibition of butyrylcholinesterase by a novel melatonin-tacrine heterodimers. J. Pineal Res. 2013;54:435–441. PubMed

Bartolucci C., Stojan J., Yu Q.S., Greig N.H., Lamba D. Kinetics of torpedo californica acetylcholinesterase inhibition by bisnorcymserine and crystal structure of the complex with its leaving group. Biochem. J. 2012;444:269–277. doi: 10.1042/BJ20111675. PubMed DOI PMC

Jokanovic M. Medical treatment of acute poisoning with organophosphorus and carbamate pesticides. Toxicol. Lett. 2009;190:107–115. doi: 10.1016/j.toxlet.2009.07.025. PubMed DOI

Ballatore C., Zhang B., Trojanowski J.Q., Lee V.M.Y., Smith A.B. In situ blood-brain barrier permeability of a c-10 paclitaxel carbamate. Bioorg. Med. Chem. Lett. 2008;18:6119–6121. doi: 10.1016/j.bmcl.2008.10.024. PubMed DOI PMC

Prades R., Guerrero S., Araya E., Molina C., Salas E., Zurita E., Selva J., Egea G., Lopez-Iglesias C., Teixido M., et al. Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor. Biomaterials. 2012;33:7194–7205. doi: 10.1016/j.biomaterials.2012.06.063. PubMed DOI

Lee N.Y., Kang Y.S. The inhibitory effect of rivastigmine and galantamine on choline transport in brain capillary endothelial cells. Biomol. Ther. 2010;18:65–70. doi: 10.4062/biomolther.2010.18.1.065. DOI

Di Stefano A., Iannitelli A., Laserra S., Sozio P. Drug delivery strategies for Alzheimer’s disease treatment. Expert Opin. Drug Deliv. 2011;8:581–603. doi: 10.1517/17425247.2011.561311. PubMed DOI

Beilin B., Bessler H., Papismedov L., Weinstock M., Shavit Y. Continuous physostigmine combined with morphine-based patient-controlled analgesia in the postoperative period. Acta Anaesthesiol. Scand. 2005;49:78–84. doi: 10.1111/j.1399-6576.2004.00548.x. PubMed DOI

Arkypova V.N., Dzyadevych S.V., Soldatkin A.P., El’skaya A.V., Martelet C., Jaffrezic-Renault N. Development and optimisation of biosensors based on ph-sensitive field effect transistors and cholinesterases for sensitive detection of solanaceous glycoalkaloids. Biosens. Bioelectron. 2003;18:1047–1053. doi: 10.1016/S0956-5663(02)00222-1. PubMed DOI

Dzyadevich S.V., Arkhypova V.N., Soldatkin A.P., El’skaya A.V., Martelet C., Jaffrezic-Renault N. Enzyme biosensor for tomatine detection in tomatoes. Anal. Lett. 2004;37:1611–1624. doi: 10.1081/AL-120037591. DOI

Benilova I.V., Arkhypova V.N., Dzyadeviych S.V., Jaffrezic-Renault N., Martelet C., Soldatkin A.P. Kinetics of human and horse sera cholinesterases inhibition with solanaceous glycoalkaloids: Study by potentiometric biosensor. Pest. Biochem. Physiol. 2006;86:203–210. doi: 10.1016/j.pestbp.2006.04.002. DOI

Ingkaninan K., Phengpa P., Yuenyongsawad S., Khorana N. Acetylcholinesterase inhibitors from stephania venosa tuber. J. Pharm. Pharmacol. 2006;58:695–700. doi: 10.1211/jpp.58.5.0015. PubMed DOI

Xiao H.T., Peng J., Liang Y., Yang J., Bai X., Hao X.Y., Yang F.M., Sun Q.Y. Acetylcholinesterase inhibitors from corydalis yanhusuo. Nat. Prod. Res. 2011;25:1418–1422. doi: 10.1080/14786410802496911. PubMed DOI

Jann M.W., Shirley K.L., Small G.W. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin. Pharmacokinet. 2002;41:719–739. doi: 10.2165/00003088-200241100-00003. PubMed DOI

Pohanka M. Acetylcholinesterase inhibitors: A patent review (2008-present) Expert Opin. Ther. Pat. 2012;22:871–886. doi: 10.1517/13543776.2012.701620. PubMed DOI

Alfirevic A., Mills T., Carr D., Barratt B.J., Jawaid A., Sherwood J., Smith J.C., Tugwood J., Hartkoorn R., Owen A., et al. Tacrine-induced liver damage: An analysis of 19 candidate genes. Pharmacogenet. Genomics. 2007;17:1091–1100. PubMed

Carr D.F., Alfirevic A., Tugwood J.D., Barratt B.J., Sherwood J., Smith J., Pirmohamed M., Park B.K. Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity. Pharmacogenet. Genomics. 2007;17:961–972. doi: 10.1097/FPC.0b013e3282f00919. PubMed DOI

Pathak M.K., Fareed M., Srivastava A.K., Pangtey B.S., Bihari V., Kuddus M., Kesavachandran C. Seasonal variations in cholinesterase activity, nerve conduction velocity and lung function among sprayers exposed to mixture of pesticides. Environ. Sci. Pollut. Res. 2013;20:7296–7300. doi: 10.1007/s11356-013-1743-5. PubMed DOI

Berg R.M.G., Ofek K., Qvist T., Tofteng F., Soreq H., Moller K. Cholinesterase modulations in patients with acute bacterial meningitis. Scand. J. Clin. Lab. Investig. 2011;71:350–352. doi: 10.3109/00365513.2011.558107. PubMed DOI

Sonali N., Tripathi M., Sagar R., Velpandian T., Subbiah V. Clinical effectiveness of rivastigmine monotherapy and combination therapy in Alzheimer’s patients. CNS Neurosci. Ther. 2013;19:91–97. doi: 10.1111/cns.12036. PubMed DOI PMC

Bond M., Rogers G., Peters J., Anderson R., Hoyle M., Miners A., Moxham T., Davis S., Thokala P., Wailoo A., et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of technology appraisal no. 111): A systematic review and economic model. Health Technol. Asses. 2012;16:1–470. PubMed PMC

Lilienfeld S. Galantamine—A novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002;8:159–176. doi: 10.1111/j.1527-3458.2002.tb00221.x. PubMed DOI PMC

Bai D.L., Tang X.C., He X.C. Huperzine a, a potential therapeutic agent for treatment of Alzheimer’s disease. Curr. Med. Chem. 2000;7:355–374. doi: 10.2174/0929867003375281. PubMed DOI

Cheewakriengkrai L., Gauthier S. A 10-year perspective on donepezil. Expert Opin. Pharmacother. 2013;14:331–338. doi: 10.1517/14656566.2013.760543. PubMed DOI

Zhang H.C., Liang H., Kuang P.Q., Yuan Q.P., Wang Y. Simultaneously preparative purification of huperzine a and huperzine b from huperzia serrata by macroporous resin and preparative high performance liquid chromatography. J. Chromatogr. B. 2012;904:65–72. doi: 10.1016/j.jchromb.2012.07.019. PubMed DOI

Zhang J.M., Hu G.Y. Huperzine a, a nootropic alkaloid, inhibits n-methyl-d-aspartate-induced current in rat dissociated hippocampal neurons. Neuroscience. 2001;105:663–669. doi: 10.1016/S0306-4522(01)00206-8. PubMed DOI

Zhang Y.H., Zhao X.Y., Chen X.Q., Wang Y., Yang H.H., Hu G.Y. Spermidine antagonizes the inhibitory effect of huperzine a on h-3 dizocilpine (mk-801) binding in synaptic membrane of rat cerebral cortex. Neurosci. Lett. 2002;319:107–110. doi: 10.1016/S0304-3940(01)02565-4. PubMed DOI

Heinrich M., Teoh H.L. Galanthamine from snowdrop—The development of a modern drug against Alzheimer’s disease from local caucasian knowledge. J. Ethnopharmacol. 2004;92:147–162. doi: 10.1016/j.jep.2004.02.012. PubMed DOI

Rainer M. Galanthamine in Alzheimer’s disease-A new alternative to tacrine? CNS Drugs. 1997;7:89–97. doi: 10.2165/00023210-199707020-00001. PubMed DOI

Pavlov V.A., Ochani M., Parrish W.R., Rosas-Ballina M., Ochani K., Al-Abed Y., Tracey K.J. The anti-inflammatory efficacy of galantamine is dependent on the integrity of the cholinergic anti-inflammatory pathway. Shock. 2007;27:23.

Takata K., Kitamura Y., Saeki M., Terada M., Kagitani S., Kitamura R., Fujikawa Y., Maelicke A., Tomimoto H., Taniguchi T., et al. Galantamine-induced amyloid-beta clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J. Biol. Chem. 2010;285:40180–40191. doi: 10.1074/jbc.M110.142356. PubMed DOI PMC

Liu Z.H., Ma Y.F., Wu J.S., Gan J.X., Xu S.W., Jiang G.Y. Effect of cholinesterase inhibitor galanthamine on circulating tumor necrosis factor alpha in rats with lipopolysaccharide-induced peritonitis. Chin. Med. J. 2010;123:1727–1730. PubMed

Hwang J., Hwang H., Lee H.W., Suk K. Microglia signaling as a target of donepezil. Neuropharmacology. 2010;58:1122–1129. doi: 10.1016/j.neuropharm.2010.02.003. PubMed DOI

Sochocka M., Zaczynska E., Leszek J., Siemieniec W., Blach-Olszewska Z. Effect of donepezil on innate antiviral immunity of human leukocytes. J. Neurol. Sci. 2008;273:75–80. PubMed

Sochocka M., Zaczynska E., Tabol A., Czarny A., Leszek J., Sobczynski M. The influence of donepezil and egb 761 on the innate immunity of human leukocytes effect on the NF-κB system. Int. Immunopharmacol. 2010;10:1505–1513. doi: 10.1016/j.intimp.2010.08.024. PubMed DOI

Tang X.C., Kindel G.H., Kozikowski A.P., Hanin I. Comparison of the effects of natural and synthetic huperzine-a on rat brain cholinergic function in vitro and in vivo. J. Enthnopharmacol. 1994;44:147–155. doi: 10.1016/0378-8741(94)01182-6. PubMed DOI

White J.D., Li Y., Kim J., Terinek M. A novel synthesis of (−)-huperzine a via tandem intramolecular aza-prins cyclization-cyclobutane fragmentation. Org. Lett. 2013;15:882–885. doi: 10.1021/ol400012s. PubMed DOI

Ma X., Gang D.R. In vitro production of huperzine a, a promising drug candidate for Alzheimer’s disease. Phytochemistry. 2008;69:2022–2028. PubMed

Leman L., Kitson S.L., Brown R.T., Cairns J., Watters W., McMordie A., Murrell V.L., Marfurt J. Synthesis of isotopically labelled c-14 zt-1 (debio-9902), d(3) zt-1 and (−)-d(3) huperzinea, a new generation of acetylcholinesterase inhibitors. J. Labelledc Compd. Rad. 2011;54:720–730. doi: 10.1002/jlcr.1918. DOI

Hedberg M.M., Clos M.V., Ratia M., Gonzalez D., Lithner C.U., Camps P., Munoz-Torrero D., Badia A., Gimenez-Llort L., Nordberg A. Effect of huprine x on beta-amyloid, synaptophysin and alpha 7 neuronal nicotinic acetylcholine receptors in the brain of 3xtg-ad and appswe transgenic mice. Neurodegener. Dis. 2010;7:379–388. doi: 10.1159/000287954. PubMed DOI

Wang J., Chen F., Zheng P., Deng W.J., Yuan J., Peng B., Wang R.C., Liu W.J., Zhao H., Wang Y.Q., et al. Huperzine a ameliorates experimental autoimmune encephalomyelitis via the suppression of t cell-mediated neuronal inflammation in mice. Exp. Neurol. 2012;236:79–87. PubMed

Wang Z.F., Tang X.C. Huperzine a protects c6 rat glioma cells against oxygen-glucose deprivation-induced injury. FEBS Lett. 2007;581:596–602. doi: 10.1016/j.febslet.2007.01.016. PubMed DOI

Wang Z.F., Wang J., Zhang H.Y., Tang X.C. Huperzine a exhibits anti-inflammatory and neuroprotective effects in a rat model of transient focal cerebral ischemia. J. Neurochem. 2008;106:1594–1603. doi: 10.1111/j.1471-4159.2008.05504.x. PubMed DOI

Darreh-Shori T., Soininen H. Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer’s disease: A review of recent clinical studies. Curr. Alzheimer Res. 2010;7:67–73. PubMed

Darreh-Shori T., Hellstrom-Lindahl E., Flores-Flores C., Guan Z.Z., Soreq H., Nordberg A. Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer’s disease patients. J. Neurochem. 2004;88:1102–1113. doi: 10.1046/j.1471-4159.2003.02230.x. PubMed DOI

Bastiat G., Plourde F., Motulsky A., Furtos A., Dumont Y., Quirion R., Fuhrmann G., Leroux J.C. Tyrosine-based rivastigmine-loaded organogels in the treatment of Alzheimer’s disease. Biomaterials. 2010;31:6031–6038. doi: 10.1016/j.biomaterials.2010.04.009. PubMed DOI PMC

Field R.H., Gossen A., Cunningham C. Prior pathology in the basal forebrain cholinergic system predisposes to inflammation-induced working memory deficits: Reconciling inflammatory and cholinergic hypotheses of delirium. J. Neurosci. 2012;32:6288–6294. doi: 10.1523/JNEUROSCI.4673-11.2012. PubMed DOI PMC

Nizri E., Irony-Tur-Sinai M., Faranesh N., Lavon I., Lavi E., Weinstock M., Brenner T. Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. J. Neuroimmunol. 2008;203:12–22. doi: 10.1016/j.jneuroim.2008.06.018. PubMed DOI

Chiou W.H., Kao C.L., Tsai J.C., Chang Y.M. Domino rh-catalyzed hydroformylation-double cyclization of o-amino cinnamyl derivatives: Applications to the formal total syntheses of physostigmine and physovenine. Chem. Commun. 2013;49:8232–8234. PubMed

Realini T. A history of glaucoma pharmacology. Optom. Vis. Sci. 2011;88:36–38. doi: 10.1097/OPX.0b013e3182058ead. PubMed DOI

Greig N.H., Becker R.E., Yu Q., Holloway H.W., Tweedie D., Luo W., Utsuki T., Ingram D.K., Maccecchini M.L., Rogers J.T., et al. From natural products to alzheimer experimental therapeutics, eserine based drugs as symptomatic and disease altering agents. Prog. Nutr. 2010;12:58–63.

Russo P., Frustaci A., del Bufalo A., Fini M., Cesario A. Multitarget drugs of plants origin acting on Alzheimer’s disease. Curr. Med. Chem. 2013;20:1686–1693. doi: 10.2174/0929867311320130008. PubMed DOI

Bitzinger D.I., Zausig Y.A., Paech C., Gruber M., Busse H., Sinner B., Graf B.M., Trabold B. Modulation of immune functions in polymorphonuclear neutrophils induced by physostigmine, but not neostigmine, independent of cholinergic neurons. Immunobiology. 2013;218:1049–1054. doi: 10.1016/j.imbio.2013.01.003. PubMed DOI

Peter C., Schmidt K., Hofer S., Stephan M., Martin E., Weigand M.A., Walther A. Effects of physostigmine on microcirculatory alterations during experimental endotoxemia. Shock. 2010;33:405–411. doi: 10.1097/SHK.0b013e3181b77e82. PubMed DOI

Kutsuna S., Tsuruta R., Fujita M., Todani M., Yagi T., Ogino Y., Igarashi M., Takahashi K., Izumi T., Kasaoka S., et al. Cholinergic agonist physostigmine suppresses excessivesuperoxide anion radical generation in blood, oxidative stress, early inflammation, and endothelial injury in rats with forebrain ischemia/reperfusion. Brain Res. 2010;1313:242–249. doi: 10.1016/j.brainres.2009.11.077. PubMed DOI

Benatar M., Kaminski H. Medical and surgical treatment for ocular myasthenia. Cochrane Database Syst. Rev. 2012;12:CD005081. PubMed PMC

Chambers D., Paulden M., Paton F., Heirs M., Duffy S., Craig D., Hunter J., Wilson J., Sculpher M., Woolacott N. Sugammadex for the reversal of muscle relaxation in general anaesthesia: A systematic review and economic assessment. Health Technol. Assess. 2010;14:1–211. PubMed

Cossins J., Belaya K., Zoltowska K., Koneczny I., Maxwell S., Jacobson L., Leite M.I., Waters P., Vincent A., Beeson D. The search for new antigenic targets in myasthenia gravis. Ann. N. Y. Acad. Sci. 2012;1275:123–128. doi: 10.1111/j.1749-6632.2012.06833.x. PubMed DOI

Vyskocil F., Malomouzh A.I., Nikolsky E.E. Non-quantal acetylcholine release at the neuromuscular junction. Physiol. Res. 2009;58:763–784. PubMed

Walker S.M., Yaksh T.L. Neuraxial analgesia in neonates and infants: A review of clinical and preclinical strategies for the development of safety and efficacy data. Anesth. Analg. 2012;115:638–662. PubMed PMC

Fisher D.M. Clinical pharmacology of neuromuscular blocking agents. Am. J. Health Syst. Pharm. 1999;56:S4–S9. PubMed

Yang L.P., Keam S.J. Sugammadex: A review of its use in anaesthetic practice. Drugs. 2009;69:919–942. doi: 10.2165/00003495-200969070-00008. PubMed DOI

Friedman A., Kaufer D., Shemer J., Hendler I., Soreq H., TurKaspa I. Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response. Nat. Med. 1996;2:1382–1385. PubMed

Kalb A., von Haefen C., Sifringer M., Tegethoff A., Paeschke N., Kostova M., Feldheiser A., Spies C.D. Acetylcholinesterase inhibitors reduce neuroinflammation and -degeneration in the cortex and hippocampus of a surgery stress rat model. PLoS One. 2013;8:e62679. PubMed PMC

Kalb A., von Haefen C., Sifringer M., Tegethoff A., Paeschke N., Kostova M., Feldheiser A., Spies C.D. Physostigmine and neostigmine reduce the increased expression of il-1beta in the hippocampus and cortex after surgery combined with lps-treatment. Eur. J. Neurol. 2012;19:756.

Pohanka M., Pavlis O. Neostigmine modulates tularemia progression in balb/c mice. Afr. J. Pharm. Pharmacol. 2012;6:1317–1322.

Sun L., Zhang G.F., Zhang X., Liu Q., Liu J.G., Su D.F., Liu C. Combined administration of anisodamine and neostigmine produces anti-shock effects: Involvement of alpha 7 nicotinic acetylcholine receptors. Acta Pharm. Sin. 2012;33:761–766. doi: 10.1038/aps.2012.26. PubMed DOI PMC

Kox M., Pompe J.C., Peters E., Vaneker M., van der Laak J.W., van der Hoeven J.G., Scheffer G.J., Hoedemaekers C.W., Pickkers P. Alpha 7 nicotinic acetylcholine receptor agonist gts-21 attenuates ventilator-induced tumour necrosis factor-alpha production and lung injury. Br. J. Anaesth. 2011;107:559–566. doi: 10.1093/bja/aer202. PubMed DOI

Caffeic Acid and Diseases-Mechanisms of Action

Acetylcholinesterase: The "Hub" for Neurodegenerative Diseases and Chemical Weapons Convention

Color Change of Phenol Red by Integrated Smart Phone Camera as a Tool for the Determination of Neurotoxic Compounds

Photography by Cameras Integrated in Smartphones as a Tool for Analytical Chemistry Represented by an Butyrylcholinesterase Activity Assay